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Abstract: The suggestion that there is a connection between chronic intraprostatic inflamma-
tion and prostate cancer was declared some years ago. As Toll-like receptors (TLRs) are the 
key players in the processes of chronic intraprostatic inflammation, there is a hypothesis that 
TLR gene polymorphisms may be associated with prostate cancer risk. Although a number of 
comprehensive studies have been conducted on large samples in various countries, reliable con-
nections between these single nucleotide polymorphisms and prostate cancer risk, stage, grade, 
aggressiveness, ability to metastasize, and mortality have not been detected. Results have also 
varied slightly in different populations. The data obtained regarding the absence of connection 
between the polymorphisms of the genes encoding interleukin-1 receptor-associated kinases 
(IRAK1 and IRAK4) and prostate cancer risk might indicate a lack of association between inher-
ited variation in the TLR signaling pathway and prostate cancer risk. It is possible to consider 
that polymorphisms of genes encoding TLRs and proteins of the TLR pathway also do not play 
a major role in the etiology and pathogenesis of prostate cancer. Feasibly, it would be better to 
focus research on associations between TLR single nucleotide polymorphisms and cancer risk 
in other infection-related cancer types.
Keywords: TLRs, single nucleotide polymorphisms, genetic variation, inflammation, innate 
immunity
Discussion
The results of a number of studies investigating the connections between sexually 
transmitted infections and prostatitis, between prostatitis and prostate cancer, and 
between genetic and circulating markers of inflammation and response to infection 
all support the hypothesis that there is a connection between chronic intraprostatic 
inflammation and prostate cancer.1 The list of causes of such inflammation includes 
exposure to various infectious agents, autoimmune disorders, damage from   mechanical 
injuries, and chemical carcinogens (as exogenous as endogenous, for instance, certain 
hormones).1
Toll-like receptors (TLRs) constitute a family of receptors that recognize pathogen-
associated and damage-associated molecular patterns, consequently playing a key role 
in innate and adaptive immune response, initiating the aforementioned inflammation. 
It has been suggested that TLR gene polymorphisms may affect TLR signaling, and, as 
a consequence, may influence TLR-mediated immune response, modulating prostate 
cancer risk.2
Since 2004, when Zheng et al2 published the first paper devoted to the investiga-
tion of the role of TLR single nucleotide polymorphisms (SNPs) in cancer etiology, a 
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  number of other studies on this subject have been carried out. 
  Nevertheless, results are rather discouraging: although Zheng 
et al2 found the rs11536889 polymorphism is associated with 
increased prostate cancer risk and Chen et al3 observed that 
the G allele of the rs2770150 polymorphism may be a high-
risk one, Lindström et al’s7 recent meta-analysis combining 
the results of Zheng et al2 and Chen et al3 with three more 
large comprehensive studies4–6 did not reveal any correlation 
between TLR gene polymorphisms and prostate cancer risk. 
In addition, no high-risk alleles were detected in a large study 
by Stevens et al,8 not included in Lindström et al’s7 pooled 
analysis. The results of all four large studies4–6,8 devoted to 
the association of polymorphisms of the TLR6-1-10 gene 
cluster with cancer risk suggest there is no correlation and 
that these SNPs cannot be considered promising for the fur-
ther analysis of their association with prostate cancer risk. 
Balistreri et al9 obtained similar null results for TLR2 and 
TLR4 SNPs.   Positive results were found only for TLR4 gene 
polymorphisms by Cheng et al10 (rs10759932, odds ratio 
[OR] = 4.62, 95% confidence interval [CI]: 1.55–13.78 for 
variant homozygous genotype), Song et al11 (rs1927911, 
OR = 2.73, 95% CI: 1.54–4.87 for heterozygous genotype; 
OR = 6.68, 95% CI: 3.27–13.66 for variant homozygous 
genotype; rs11536858, OR = 2.3, 95% CI: 1.07–4.93 
for heterozygous genotype), Wang et al12 (rs10116253, 
OR = 3.05, 95% CI: 1.11–8.41 for variant homozygous 
genotype), and Kim et al13 (rs11536889, OR = 1.81, 95% 
CI: 1.29–2.53 for heterozygous genotype). However, these 
SNPs were not detected as risk factors in   Lindström et al’s7 
meta-analysis and therefore it is not possible to consider 
them as definite risk factors overall.   Additionally, Shui et al,14 
who carried out the most recent large investigation on this 
subject, did not detect any association between TLR4 gene 
polymorphisms and prostate cancer risk. The results of all 
studies mentioned are summarized in Tables 1 and 2.
All of those who have investigated the association 
between TLR gene polymorphisms and features of prostate 
cancer pathogenesis (stage, aggressiveness, Gleason grade, 
metastases), as well as the association between TLR gene 
polymorphisms and prostate cancer mortality, obtained nega-
tive results. This suggests there is no connection between 
TLR gene polymorphisms and the pathogenetic peculiarities 
of prostate cancer.2–4,6,7,11,13,14
The active investigation of a correlation between TLR SNPs 
and prostate cancer is intriguing. Despite there being some 
fundamental mechanisms that indicate TLR gene polymor-
phisms may play a role in prostate cancer etiology, and despite 
there being a number of comprehensive studies   conducted 
Table 1 Association of TLR2 and TLR4 gene polymorphisms with 
prostate cancer risk
Reference SNP Sample size OR (95% CI)*
TLR2
Balistreri  
et al9  
(Italian  
population)
rs5743708 50 cases,  
125 controls,  
55 male  
centenarians
nA
2029C/T nA  
(with age-matched  
controls)
TLR4
Zheng et al2 
(Swedish  
population)
rs11536889 1383 cases,  
780 controls
Carriers of  
C allele: 1.26  
(1.01–1.57) 
[Before 65 years:  
1.39 (1.02–1.91)]
rs5030721 nA
rs4986790 nA
rs2149356 nA
Chen  
et al3 (US  
population)
rs2770150 700 cases,  
700 controls
Carriers of one  
G allele: 1.38  
(1.10–1.73)
rs11536858 nA
rs6478317 Carriers of GG  
genotype: 0.66  
(0.46–0.94)
rs10116253 Carriers of CC  
genotype: 0.59  
(0.39–0.90)
rs1927914 Carriers of GG  
genotype: 0.64  
(0.45–0.93)
rs10759932 Carriers of one  
C allele: 0.73  
(0.57–0.93)
rs1927911 Carriers of AA  
genotype: 0.63  
(0.41–0.95)
rs11536878 nA
rs5030717 Carriers of one  
G allele: 0.66  
(0.51–0.86)
rs2149356 Carriers of TT  
genotype: 0.64  
(0.45–0.91)
rs4986790 nA
rs11536889 nA
rs7873784 Carriers of CC  
genotype: 0.51  
(0.28–0.96)
rs11536891 Carriers of CC  
genotype: 0.50  
(0.27–0.95)
rs11536897 nA
rs1536898 Carriers of AA  
genotype: 0.38  
(0.16–0.92)
Cheng  
et al10 (US  
population)
rs10759932 506 cases,  
506 controls
Carriers of CC  
genotype: 4.62  
(1.55–13.78)
rs2149356 nA
(Continued)
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Table 1 (Continued)
Reference SNP Sample size OR (95% CI)*
rs5030728 Carriers of AA  
genotype: 0.91  
(0.70–1.19)
rs4986790 nA
rs11536889 nA
rs7873784 nA
Yeager et al5  
(European  
population)
rs1928298 1172 cases,  
1157 controls
nA
rs1360094 nA
rs4837496 nA
rs10818070 nA
rs10759930 nA
rs2737191 nA
rs2770150 nA
rs6478317 nA
rs10116253 nA
rs1927914 nA
rs10759932 nA
rs1927911 nA
rs11536879 nA
rs5030717 nA
rs2149356 nA
rs4986790 nA
rs7873784 nA
rs11536897 nA
rs1927906 nA
rs11536898 nA
rs1554973 nA
rs913930 nA
rs1927905 nA
rs7045953 nA
Song et al11  
(Korean  
population)
rs1927911 157 cases,  
143 controls
Carriers of TC  
genotype: 2.73  
(1.54–4.87) 
Carriers of CC  
genotype: 6.68  
(3.27–13.66)
rs11536858 Carriers of GG  
genotype: 2.3  
(1.07–4.93)
rs1927914 nA
rs11536891 nA
rs11536897 nA
Wang  
et al12 (US  
population)
rs4986790 258 cases,  
258 controls
Carriers of G  
allele: 0.60  
(0.33–1.08) 
[Men younger  
than 65 years: 0.26  
(0.08–0.87)]
rs11536889 Carriers of C  
allele: 0.50  
(0.28–0.89)  
(patients with normal   
cholesterol) 
1.65 (0.98–2.78) 
(patients with 
elevated cholesterol)
(Continued)
Table 1 (Continued)
Reference SNP Sample size OR (95% CI)*
rs10116253 Carriers of CC  
genotype: 3.05  
(1.11–8.41)
rs1927911 nA
rs1927914 nA
rs2149356 nA
rs7873784 nA
rs11536891 nA
rs11536898 nA
rs2737190 nA
Balistreri  
et al9  
(Italian  
population)
rs4986790 50 cases, 125 age- 
matched controls,  
55 centenarian  
controls
nA
rs4986791 nA (with  
age-matched 
controls)
Lindström  
et al7  
(meta-analysis  
of Zheng  
et al,2  
Chen et al,3  
and Yeager  
et al5)
rs1928298 Pooled analysis:  
3101 cases,  
2253 controls
nA
rs1360094 nA
rs4837496 nA
rs10818070 nA
rs10759930 nA
rs2737191 nA
rs2770150 nA
rs11536858 nA
rs6478317 nA
rs10116253 nA
rs1927914 nA
rs10759932 nA
rs1927911 nA
rs10759933 nA
rs11536871 nA
rs11536879 nA
rs5030317 nA
rs2149356 nA
rs4986790 nA
rs5030721 nA
rs11536889 nA
rs7873784 nA
rs11536891 nA
rs11536897 nA
rs1927906 nA
rs11536898 nA
rs1554973 nA
rs913930 nA
rs1927905 nA
rs7045953 nA
Kim et al13  
(Korean  
population)
rs10983755 240 cases,  
223 controls
nA
rs10759932 nA
(Continued)
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Table 1 (Continued)
Reference SNP Sample size OR (95% CI)*
rs1927911 nA
rs11536879 nA
rs12377632 nA
rs5030717 nA
rs2149356 nA
rs5030718 nA
rs7869402 nA
rs11536889 1.81 (1.29–2.53)  
(for heterozygous  
genotype)
rs7873784 nA
Shui  
et al14 (US  
population)
Ten TLR4 gene  
polymorphisms
1286 cases,  
1267 controls
nA
nA
nA
nA
nA
nA
nA
nA
nA
nA
Note: *Only positive or negative statistically significant results.
Abbreviations:  CI,  confidence  interval;  NA,  no  association;  OR,  odds  ratio;   
SNP, single nucleotide polymorphism; TLR, Toll-like receptor; US, United States.
on large samples in various countries, reliable connections 
between these SNPs and prostate cancer risk or features of 
prostate cancer progression have not been detected. Results 
have also varied slightly in different populations. However, it 
is possible that some of the TLR gene polymorphisms may be 
the markers of prostate cancer risk in certain populations (eg, 
rs5743795, rs5743551, rs5743556, rs5743604, rs4274855, 
rs11096957, rs11096955, and rs4129009 in the Swedish 
population;4 rs11536889 in the Swedish and the Korean 
populations;2,13 rs2770150, s10759932, and rs10116253 in the 
US population;3,10,12 rs1927911 and rs11536858 in the Korean 
population11). However, Lindström et al’s7 meta-analysis, in 
which all of the populations mentioned above were consid-
ered, revealed that TLR gene polymorphisms cannot be the 
markers of prostate cancer overall and therefore they should 
be considered as risk markers, even in populations where the 
association has been found.7 Apparently, the lack of sample 
size was not the reason for negative results in either the general 
meta-analysis or in specific studies in particular populations, 
because the investigations in Swedish,2,4,15 European,5 and US 
populations3,6,8,10,12 included a large number of case and control 
subjects. Although two Korean studies11,13 had relatively small 
sample sizes, a recent large study in the Korean population also 
Table 2 Association of polymorphisms of TLR6-1-10 gene cluster 
with prostate cancer risk
Reference SNP Sample size OR (95% CI)*
Stevens  
et al8 (US  
population)
TLR10: 
rs4129009  
(MAF 18%–18.5%)
1414 cases,  
1414 controls
nA
rs11466657  
(MAF 3.09%–3.38%)
nA
rs11466655  
(MAF 0.72%–0.76%)
nA
rs11096955  
(MAF 32.6%–35.8%)
A/C compared  
with A/A: 0.84  
(0.72–0.98) 
C/C compared  
with A/A: 0.78  
(0.61–0.99)
rs11096956  
(MAF 21.1%–23.5%)
nA
rs11466653  
(MAF 2.94%–3.93%)
nA
rs11466651  
(MAF 3.14%–3.74%)
nA
rs11096957  
(MAF 32.6%–35.8%)
A/C compared  
with A/A: 0.84  
(0.72–0.98) 
C/C compared  
with A/A: 0.78  
(0.61–0.99)
rs11466649  
(MAF 3.3%–3.84%)
nA
rs10856838  
(MAF 14.7%–16.4%)
nA
rs4274855  
(MAF 18%–18.5%)
nA
rs11466640  
(MAF 18.1%–18.6%)
nA
rs11466617  
(MAF 18%–18.6%)
nA
rs7653908  
(MAF 21.1%–20.6%)
nA
rs7658893  
(MAF 23.6%–25.2%)
nA
TLR1: 
rs4624663  
(MAF 2.46%–2.18%)
nA
rs4833095  
(MAF 23.4%–26.8%)
T/C compared  
with T/T: 0.90  
(0.77–1.05)  
C/C compared 
with TT/T: 0.64  
(0.47–0.86)
rs5743611  
(MAF 8.6%–8.8%)
nA
rs5743604  
(MAF 23.9%–24.2%)
nA
rs5743596  
(MAF 14.9%–18.5%)
C/T compared  
with C/C: 0.79  
(0.66–0.93) 
(Continued)
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Table 2 (Continued)
Reference SNP Sample size OR (95% CI)*
T/T compared 
with C/C: 0.59  
(0.38–0.91)
rs5743595  
(MAF 17.4%–20.6%)
T/C compared  
with T/T: 0.82  
(0.70–0.97) 
C/C compared  
with T/T: 0.63  
(0.42–0.93)
rs5743594  
(MAF 19.8%–17.7%)
nA
rs5743556  
(MAF 19%–19.6%)
nA
rs5743551  
(MAF 23.7%–26.7%)
A/G compared  
with A/A: 0.90  
(0.77–1.06) 
G/G compared  
with A/A: 0.67  
(0.50–0.91)
TLR6: 
rs5743815  
(MAF 1.91%–1.27%)
nA
rs5743810  
(MAF 42.1%–42.7%)
nA
rs5743806  
(MAF 30.3%–30.6%)
nA
rs5743795  
(MAF 19.9%–20.2%)
nA
Chen  
et al6 (US  
population)
rs5743788  
(MAF 50%–49%)
659 cases,  
656 controls
nA
rs5743795  
(MAF 19%–21%)
nA
rs5743806  
(MAF 31%–30%)
nA
rs1039599  
(MAF 46%–46%)
nA
rs5743810  
(MAF 42%–41%)
nA
rs3821985  
(MAF 34%–33%)
nA
rs5743815  
(MAF 1%–2%)
nA
rs5743551  
(MAF 24%–26%)
nA
rs5743556  
(MAF 18%–19%)
nA
rs5743604  
(MAF 23%–26%)
nA
rs5743611  
(MAF 8%–9%)
nA
rs4624663  
(MAF 4%–4%)
nA
rs11466617  
(MAF 17%–18%)
nA
rs11466640  
(MAF 17%–19%)
nA
(Continued)
Table 2 (Continued)
Reference SNP Sample size OR (95% CI)*
rs4274855  
(MAF 18%–19%)
nA
rs11096957  
(MAF 33%–36%)
nA
rs11096955  
(MAF 33%–36%)
nA
rs11466657  
MAF (4%–4%)
nA
rs4129009  
(MAF 17%–18%)
nA
Yeager et al5  
(European  
population)
rs10008492 1172 cases,  
1157 controls
nA
 
rs4331786
 
nA
rs11466657 nA
rs11096957 nA
rs10856839 nA
rs11466640 nA
rs11466619 nA
rs11466612 nA
rs7663239 nA
rs4543123 nA
rs4833095 nA
rs5743594 nA
rs5743563 nA
rs4833103 nA
rs7696175 nA
rs5743810 nA
rs1039559 nA
rs6833914 nA
rs6531673 nA
Sun et al4  
(Swedish  
population)
TLR6: 
2113 C/G  
(73.76%–76.35%  
C/G and G/G)
1383 cases,  
780 controls
nA
rs5743795  
(32.8%–26.24%  
A/G and AA)
A/G and A/A  
compared with  
G/G: 1.38  
(1.12–1.70)
rs5743806  
(89.12%–89.33%  
C/T and T/T)
C/T and T/T  
compared with  
C/C: 0.98  
(0.73–1.31)
rs5743810  
(82.84%–82.84%  
C/T and C/C)
nA
rs5743815  
(3.44%–2.9%  
C/T and C/C)
nA
TLR1: 
rs5743551  
(40.16%–34.32%  
A/G and G/G)
A/G and G/G  
compared  
with A/A: 1.29  
(1.06–1.56)
rs5743556  
(32.67%–26.65%  
C/T and C/C)
C/T and C/C  
compared with  
T/T: 1.33  
(1.09–1.62)
(Continued)
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Table 2 (Continued)
Reference SNP Sample size OR (95% CI)*
rs5743604  
(42.1%–35.69%  
C/T and C/C)
C/T and C/C  
compared with  
T/T: 1.30  
(1.08–1.60)
rs5743611  
(98.35%–98.21%  
G/C and G/G)
nA
rs4624663  
(7.79%–7.16%  
G/A and G/G)
nA
TLR10: 
3260C/T  
(29.79%–26.06%  
T/C and C/C)
T/C and C/C  
compared with  
T/T: 1.20  
(0.99–1.46)
1692C/T  
(30.34%–26.04%  
C/T and T/T)
C/T and T/T  
compared with  
C/C: 1.23  
(1.01–1.50)
rs4274855  
(32.04%–26.93%  
A/G and A/A)
A/G and A/A  
compared with  
G/G: 1.27  
(1.04–1.56)
rs11096957  
(60.18%–55.85%  
A/C and C/C)
A/C and C/C  
compared with  
A/A: 1.20  
(1.00–1.43)
rs11096955  
(57.19%–51.70%  
A/C and C/C)
A/C and C/C  
compared with  
A/A: 1.25  
(1.04–1.50)
rs11466657  
(4.39%–4.08% T/C)
nA
rs4129009  
(31.20%–26.31%  
G/A and G/G)
G/A and G/G  
compared with  
A/A: 1.26  
(1.03–1.54)
Lindström  
et al7  
(meta-analysis  
of Sun et al,4  
Chen et al,6  
and Yeager  
et al5)
rs10008492 3101 cases,  
2523 controls
nA
rs4331786 nA
rs4129009 nA
rs11466657 nA
rs11096955 nA
rs11096957 nA
rs10856839 nA
rs4274855 nA
rs11466640 nA
rs11466619 nA
rs11466617 nA
rs11466612 nA
rs7663239 nA
rs4543123 nA
rs4624663 nA
(Continued)
Table 2 (Continued)
Reference SNP Sample size OR (95% CI)*
rs4833095 nA
rs5743611 nA
rs5743604 nA
rs5743594 nA
rs5743563 nA
rs5743556 nA
rs5743551 nA
rs4833103 nA
rs7696175 nA
rs5743815 nA
rs3821985 nA
rs5743810 nA
rs1039559 nA
rs5743806 nA
rs5743795 nA
rs5743788 nA
rs6833914 nA
rs6531673 nA
Note: *Only positive or negative statistically significant results.
Abbreviations: CI, confidence interval; MAF, minor allele frequency; OR, odds 
ratio; SNP, single nucleotide polymorphism; TLR, Toll-like receptor.
obtained negative results.14 Therefore, the statistical power of 
almost all of the studies was sufficient.   Population   stratification 
in various studies revealed no subcategorical differences 
when compared with general results, although a dependence 
of association on age was found in one study in the Swedish 
population,2 and cholesterol level was found to influence the 
association in one study in the US population.12 However, 
alone these results cannot provide sufficient information on 
the subcategorical modification of association of TLR gene 
polymorphisms with prostate cancer. In addition, there are 
no studies considering the gene-gene and gene-environment 
interactions in relation to prostate cancer.
Sun et al15 did not observe any correlation between 
polymorphisms of the genes encoding the interleukin-1 
receptor-associated kinases (IRAK1 and IRAK4) and prostate 
cancer. The data obtained by Sun et al15 might also reflect 
a lack of association between inherited variation in genes 
encoding proteins of the TLR signaling pathway and pros-
tate cancer risk, since IRAK1 and IRAK4 are key proteins 
of this pathway.
Conclusion
In conclusion, it is possible to suggest that TLR and TLR 
pathway gene polymorphisms do not play a major role in the 
etiology of prostate cancer, although in certain populations 
their minor role can be established. Feasibly, it would be bet-
ter to focus research on associations between TLR SNPs and 
cancer risk in other infection-related cancer types.
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